苏格兰卫生监管机构批准为苏格兰国民保健制度提供五种新药品。 Scotland's health regulator approves five new medications for NHS Scotland.

苏格兰的卫生监管机构苏格兰药物联盟 (SMC) 已批准了苏格兰国家卫生服务局 (NHS) 提供的五种新药,包括治疗多发性骨髓瘤的Selinexor,治疗高危非小细胞肺癌的Pembrolizumab和治疗激素敏感前列腺癌的Relugolix. Scotland's health regulator, the Scottish Medicines Consortium (SMC), has approved five new medications for NHS Scotland, including Selinexor for multiple myeloma, Pembrolizumab for high-risk non-small cell lung cancer, and Relugolix for advanced hormone-sensitive prostate cancer. 这些治疗被视为病人的“游戏变换者”,加强了联合王国各地的无障碍和安全。 These treatments are deemed "game-changers" for patients, enhancing accessibility and safety across the UK. 其他批准包括入侵性直肠病的Rezafungin和视力障碍的Faricimab。 Additional approvals include Rezafungin for invasive candidiasis and Faricimab for vision impairment.

October 07, 2024

3 文章